Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin 20 receptor subunit beta (IL20RB)
- Target
- IL20RB
- Molecular classification
- Receptor, Cytokine receptor, Class II cytokine receptor
01
Overview
Interleukin 20 receptor subunit beta (IL20RB) is a type II cytokine receptor subunit that partners with other subunits (IL20RA or IL22RA1) to form heterodimeric receptors for interleukin-19, interleukin-20, and interleukin-24. These receptor complexes are expressed on epithelial, immune, and organ-resident effector cells and mediate both pro-inflammatory and anti-inflammatory functions through the JAK/STAT signaling pathway. IL20RB-containing receptors play regulatory roles in immunity and tissue homeostasis and are implicated in the development and pathogenesis of multiple inflammatory and autoimmune diseases, such as psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, glaucoma, and gastrointestinal conditions.
- Other names
- IL20RBIL-20R2DIRS1FNDC6 (fibronectin type III domain containing 6)Interleukin 20 receptor beta
02
Mechanism of action
Blockade or modulation of cytokine-receptor interaction (e.g., antibodies or small molecules inhibiting binding of IL-19, IL-20, or IL-24 to IL20RB-containing heterodimers); Inhibition of downstream JAK/STAT signaling
03
Biological functions
Signal transduction (via JAK/STAT pathway)Immune response regulationPro-inflammatory responseAnti-inflammatory responseRegulation of epithelial functionCell proliferation
04
Disease associations
Inflammation (e.g., psoriasis, rheumatoid arthritis)Autoimmune diseaseOsteoporosisAtherosclerosisGlaucomaGastrointestinal diseases
05
Safety considerations
Modulation of immune function carries risks of infection, impaired epithelial repair, or off-target immune suppressionPossible cytokine signaling cross-talk and redundancy, which may complicate therapeutic strategiesPotential for exacerbating inflammation with improper targeting
06
Biomarkers
IL20RB expression as a tissue or disease biomarker (e.g., skin, immune cells in diseases like psoriasis or rheumatoid arthritis)Expression levels (by RT-PCR, IHC) may help select patients or monitor treatment response in clinical studies
Beyond the preview
Go deeper on Interleukin 20 receptor subunit beta (IL20RB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interleukin 20 receptor subunit beta (IL20RB).